Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritinib Adjuvant Therapy in Resected EGFR-Mutated NSCLC
NCT06080776Phase 3Recruiting
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- May 2023
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd.. Started May 2023; status: recruiting.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06080776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06080776.